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Autoimmune Diabetes
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OBJECTIVE—There is evidence that monocytes of patients
with type 1 diabetes show proinflammatory activation and dis-
turbed migration/adhesion, but the evidence is inconsistent. Our
hypothesis is that monocytes are distinctly activated/disturbed in
different subforms of autoimmune diabetes.
RESEARCH DESIGN AND METHODS—We studied patterns
of inflammatory gene expression in monocytes of patients with
type 1 diabetes (juvenile onset, n  30; adult onset, n  30) and
latent autoimmune diabetes of the adult (LADA) (n  30)
(controls subjects, n 49; type 2 diabetic patients, n 30) using
quantitative PCR. We tested 25 selected genes: 12 genes detected
in a prestudy via whole-genome analyses plus an additional 13
genes identified as part of a monocyte inflammatory signature
previously reported.
RESULTS—We identified two distinct monocyte gene expres-
sion clusters in autoimmune diabetes. One cluster (comprising
12 proinflammatory cytokine/compound genes with a putative
key gene PDE4B) was detected in 60% of LADA and 28% of
adult-onset type 1 diabetic patients but in only 10% of juvenile-
onset type 1 diabetic patients. A second cluster (comprising 10
chemotaxis, adhesion, motility, and metabolism genes) was
detected in 43% of juvenile-onset type 1 diabetic and 33% of
LADA patients but in only 9% of adult-onset type 1 diabetic
patients.
CONCLUSIONS—Subgroups of type 1 diabetic patients show
an abnormal monocyte gene expression with two profiles, sup-
porting a concept of heterogeneity in the pathogenesis of auto-
immune diabetes only partly overlapping with the presently
known diagnostic categories. Diabetes 57:2768–2773, 2008
There is evidence that monocytes of patients withtype 1 diabetes are functionally aberrant, show-ing raised production of interleukin (IL)-1, IL-6,superoxide anion, and prostaglandin-endoperox-
ide synthase 2 (PTGS2) (1–3); aberrant generation of
antigen-presenting cells (4,5); and abnormal chemotaxis,
adhesion, and migratory potential (6). These aberrancies
are thought to play a role in the pathogenesis of the
disease by disrupting tolerance and aggravating the -cell
cytotoxic potential of infiltrating monocyte-derived den-
dritic cells and macrophages. However, these aberrant
functional findings could not always be reproduced, par-
ticularly with regard to the enhanced production of PTGS2
(7) and the poor generation of antigen-presenting cells
from monocytes (8). Two issues could be relevant to these
discrepancies. First, raised production of proinflammatory
monocyte-derived cytokines could be related to hypergly-
cemia (9). Second, there might be heterogeneity within
autoimmune diabetes, such as has been noted previously
between adult and juvenile forms of type 1 diabetes on the
basis of genetic, immune, and metabolic characteristics
(10). This possible heterogeneity in autoimmune diabetes
might also become evident in different monocyte activa-
tion profiles.
To resolve these issues, we focus here on patterns of
inflammatory gene expression in monocytes from selected
patients distinguished by clinical characteristics and age at
diagnosis, as well as from control subjects. Our hypothesis
is that monocytes might be distinctly activated and dis-
turbed within the known diagnostic categories of diabetes.
Recently, we reported a signature of 18 inflammatory-
related genes in monocytes of bipolar patients (11); acti-
vated monocytes are thought to play a role in the
pathogenesis of bipolar disorder (12,13). Given the re-
ported association between bipolar disorder and auto-
immune diabetes (14), and given the possible central role
of monocytes in both disorders, we tested this set of 18
proinflammatory monocyte genes in patients with auto-
immune diabetes. To these 18 monocyte genes, we added
7 genes identified in a whole-genome expression profile of
a set of juvenile-onset type 1 diabetic patients who had
been compared with healthy control subjects and type 2
diabetic patients (see supplementary Fig. 1 [available in an
online appendix at http://dx.doi.org/10.2337/db08-0496]).
Thus, using quantitative RT-PCR (Q-PCR), we validated
abnormal expression of 25 monocyte activation genes in
latent autoimmune diabetes of the adult (LADA), adult-
onset type 1 diabetic and juvenile-onset type 1 diabetic
patients, and, as controls, type 2 diabetic patients and
healthy subjects.
RESEARCH DESIGN AND METHODS
All participants were diagnosed with diabetes according to the criteria of the
American Diabetes Association (15). The characteristics of both patients and
control subjects are shown in a supplementary Table A.
The methods of blood collection and storage, preparation of purified
CD14 monocytes, mRNA isolation, and Q-PCR have been described in
detail elsewhere (11) and are given in the legend of supplementary Table
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B. Statistics used have been given in the legends of the various tables and
figures.
RESULTS
Q-PCR analysis. Table 1 shows the gene expression
levels of 24 of 25 selected genes in the monocytes of the
tested diabetic groups. These 25 genes comprised 12 genes
(10 upregulated and 2 downregulated), identified in a
prestudy (Affymetrix gene expression profiling, supple-
mentary Fig. 1), that differentiated type 1 diabetes mono-
cytes from both type 2 diabetes and control monocytes
(fourfold difference, P  0.01). These 12 genes were
STX1A, DHRS3 (SDR1), FABP5, CD9, CDC42, chemokine
ligand 2 (CCL2), CCL7 (MCP-3), PTPN7, NAB2, and
EMP1 (all upregulated) and BAZ1A and HSPA1A (each
downregulated). The other 13 genes we tested (PDE4B,
IL1B, IL6, tumor necrosis factor (TNF), PTGS2, pen-
traxin 3 (PTX3), CCL20, CXCL2, MAPK6, DUSP2, ATF3,
TNFAIP3, and BCL2A1) were reported elsewhere (11) as
a coherent and mutually correlating set (signature) of 18
aberrantly expressed inflammation-related genes in mono-
cytes of bipolar patients; 5 of the 18 genes, i.e., CDC42,
CCL2, CCL7, NAB2, and EMP1, were also detected in our
Affymetrix prestudy in purified type 1 diabetes monocytes.
In Table 1, data are given as relative fold changes, a
method that is widely used but that has potential limita-
tions (e.g., less accurate for genes with a large difference
from the reference gene; for raw cycle threshold values
see supplementary Table C), as does our standardization
of patient data to control subjects (which was done to
correct for the observed interassay variation). To address
the latter issue, data were also analyzed before standard-
ization to control subjects (supplementary Table D). In
essence, the same conclusions can be drawn from both
analyses: 1) 24 of 25 studied genes were validated as
aberrantly expressed (BAZ1A was not abnormally ex-
pressed); 2) although monocytes of juvenile-onset type 1
diabetic, adult-onset type 1 diabetic, LADA, and type 2
diabetic patients all showed enhanced gene expression of
many of the inflammatory genes compared with control
subjects, they also showed differences compared with
each other; and 3) some of the genes were specific for a
diagnostic category. The upregulation of PDE4B, TNFAIP3,
and MAPK6 were specific for LADA monocytes; the upregu-
lation of FABP5 and the downregulation of HSPA1A were
specific for juvenile-onset type 1 diabetes monocytes. Nei-
ther adult-onset type 1 diabetes nor type 2 diabetes had an
up- or downregulation of a specific gene, although type 2
diabetes monocytes showed a clear upregulation of many of
the inflammatory genes.
The gene expression levels within each subject group
did not correlate with A1C, BMI, age, sex, age at onset of
diabetes, or disease duration (tested by ANCOVA). To
further analyze the data, we embarked on cluster analysis.
Identification of two gene expression clusters and
their presence in LADA, type 1 diabetic, and type 2
diabetic patients. Figure 1 shows the Q-PCR data of the
patients and control subjects in hierarchical cluster anal-
ysis. The dendrogram of average linkage showed two
interdependent main gene clusters.
In another and different cluster analysis of the Q-PCR
data, we correlated the expression levels of the 24 abnor-
mally expressed genes to the expression level of the
following: 1) PDE4B, because it is one of the genes
specific for LADA and a putative key gene for cluster 1
(see DISCUSSION), and 2) FABP5, because this cluster 2 gene
is specific for juvenile-onset type 1 diabetes. Table 2 shows
that around these specific genes, two mutually correlating
gene expression sets appeared. In the PDE4B-correlating
set, all cluster 1 and cluster 2 genes (apart from FABP5)
were present and correlated strongly with the gene expres-
sion of PDE4B. In the FABP5-correlating set, almost all
cluster 2 genes were present (except for NAB2), along
with CXCL2, PTGS2, HSPA1A, and CD9. Interestingly,
PTGS2 was overexpressed in the PDE4B-positive sub-
jects, whereas its expression was reduced in FABP5-
positive subjects (Table 2).
We next sought the relationship of different patient
groups to cluster 1 and cluster 2 genes (Table 3). Cluster 1
and the PDE4B-correlating set were significantly more
frequent in adult-onset type 1 diabetic, LADA, and type 2
diabetic patients compared with control subjects, whereas
control subjects and juvenile-onset type 1 diabetic patients
were similar in this regard. Cluster 2 and the FABP5-
correlating set were significantly more frequent in both
juvenile-onset type 1 diabetic and LADA patients com-
pared with control subjects, adult-onset type 1 diabetic,
and type 2 diabetic patients. Neither clusters nor specific
PDE4B or FABP5 gene expression were related to age,
A1C, glucose level, or BMI within any of the groups
studied.
Correlations between gene expression levels in cir-
culating monocytes and serum levels of cytokines. In
addition to monocyte gene analysis, we determined serum
levels of IL-6, tumor necrosis factor–, pentraxin 3
(PTX3), and CCL2 in patients and control subjects (for
data see supplementary Fig. 2) and correlated gene ex-
pression levels to corresponding serum cytokine levels.
Monocyte gene expression levels of PTX3 and IL6 (PTX3:
r  0.26, P  0.004; IL-6: r  0.23, P  0.034; Spearman’s
correlation), but not of TNF and CCL2, correlated with
serum protein levels. A possible explanation for this
observed discrepancy between mRNA and protein expres-
sion levels is that serum levels of cytokines are more
subject to confounders (e.g., BMI, glucose levels) than
gene expression levels, as is suggested by our data (sup-
plementary Fig. 2).
We also compared the serum cytokine levels of cluster-
positive and cluster-negative patients. We found higher
serum levels of PTX3 in cluster 1–positive compared with
cluster 1–negative patients (Fig. 2), suggesting an in vivo
relevance of at least cluster 1 gene expression. Elevated
levels of serum PTX3, a novel acute phase protein, have
been found in other autoimmune conditions such as
rheumatoid arthritis and scleroderma (16).
DISCUSSION
This study shows two distinct monocyte gene-expression
profiles in autoimmune diabetes, indicating different acti-
vation profiles, which suggests heterogeneity in the patho-
genesis of autoimmune diabetes.
We identified one profile of mainly proinflammatory
genes (IL1B, IL6, TNF, PTGS2, PTX3, CCL20, CXCL2,
DUSP2, ATF3, TNFAIP3, and BCL2A1) with a putative
key gene PDE4B. PDE4B is a c-AMP–degrading enzyme
and could be a key molecule for turning monocytes into
high proinflammatory cytokine–producing cells, as tar-
geted gene knockout studies show that phosphodiesterase
4B (PDE4B) has a crucial role in the cytokine production
of monocytes (17–20). A second profile consisted of genes
mainly involved in chemotaxis, adhesion, motility, and
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metabolism (CCL7, CCL2, CDC42, STX1A, EMP1, FABP5,
DHRS3, NAB2, PTPN7, and MAPK6), with a putative key
gene FABP5.
The first profile (cluster 1) was found in monocytes in
LADA (60%) and adult-onset type 1 diabetic patients (28%)
more than in juvenile-onset type 1 diabetic patients and
control subjects (each 10%). The second profile (cluster 2),
conversely, was found in 43% of juvenile-onset type 1
diabetic and in 33% of LADA patients but in 10% each of
adult-onset type 1 diabetic patients and control subjects.
These different frequencies of the two activation clusters
in the known diagnostic categories of diabetes are consis-
tent with the view that the categories are pathologically
different, such that LADA and adult-onset type 1 diabetes
have similar immune characteristics distinct from juvenile-
onset type 1 diabetes (10).
We also found many of the inflammatory genes upregu-
lated in type 2 diabetes monocytes, supporting the view
that inflammatory monocytes are involved in the patho-
genesis of type 2 diabetes (21). However, most (83–100%)
type 2 diabetic patients had normal expression of the key
genes PDE4B and FABP5, which resulted in their mono-
cyte gene cluster being distinct from that in the majority of
LADA and juvenile-onset type 1 diabetic patients.
Because the monocytes appear to be distinctly acti-
vated and disturbed in LADA, adult-onset type 1 diabe-
tes, juvenile-onset type 1 diabetes, and type 2 diabetes, it
is possible that these profiles can be used to identify
subforms of diabetes within the known diagnostic catego-
ries of diabetes. This subdivision could improve outcome
prediction and gene-association studies, may lead to more
consistent reports on immune aberrancies in autoimmune
diabetes, and could result in new intervention strategies
by providing new targets for treatment. PDE4B, in partic-
ular, might be such a target, as inhibitors are in develop-
ment (17–20), and rolipram, an archetypical PDE4
inhibitor, reduced insulitis and prevented diabetes in the
nonobese diabetic (NOD) mouse (22). Another potential
target for drug intervention is PTGS2, a key enzyme in the
biosynthesis of prostanoids. COX-2 (PTGS2) inhibitors are
well known for their anti-inflammatory functions (23), but
there are no studies of them in diabetic patients. Of note,
both a raised and normal basal PTGS2 have been de-
scribed in type 1 diabetes (3,7); here we find that PTGS2 is
raised in cluster 1 but downregulated in cluster 2–positive
type 1 diabetic patients. Thus, COX-2 inhibitors might alter
monocyte activation in cluster 1–positive patients (i.e.,
many LADA and adult-onset type 1 diabetic patients) but
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FIG. 1. Color-coded correlation matrix illustrating pairwise correlations between the expression levels of the 24 genes aberrantly expressed
in patients with various forms of diabetes (Table 1). Blue squares indicate negative correlations; red squares indicate positive correlations.
The color intensities code for the strength of the correlations. Also, a dendrogram is presented as a result of hierarchical cluster analysis
with the use of correlation coefficients. The dendrogram shows two gene-expression clusters.
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not in cluster 2–positive patients (i.e., many juvenile-onset
type 1 diabetic patients).
A recent study (24) showed that factors in serum of type
1 diabetic patients could induce inflammatory genes
(CCL2, CCL7, IL1B) in peripheral blood mononuclear
cells (PBMCs). Another gene expression study of PBMCs
of type 1 diabetic patients (25) also detected overexpres-
sion of inflammatory genes (among others, IL1B and
PTGS2), without evidence of the extended signatures
described here. In this latter study, investigators used
nonfractionated PBMCs. Indeed, an important issue is the
cell collection, preservation, and separation used in our
study. We used frozen-stored PBMCs and positive CD14
magnetic cell sorting separation. Specifically, freeze-stor-
ing might induce differences in gene expression, whereas
positive magnetic cell sorting separation does not influ-
ence gene expression (11,26). Alternative monocyte sepa-
ration techniques do modify gene expression profiles, e.g.,
we found plastic adhered monocytes to downregulate
PDE4B gene expression (as is known when monocytes
change into macrophages [27]). However, despite these
limitations, the differences we describe cannot be due to
freeze storage because all monocytes are handled simi-
TABLE 2
Correlation of mRNAs
PDE4B correlating set FABP5 correlating set
Gene r P Gene r P
PDE4B 1 PDE4B 0.011 0.96
CCL20 0.88 0.001 CCL20 0.20 0.39
DUSP2 0.88 0.001 DUSP2 0.14 0.45
IL1B 0.87 0.001 IL1B 0.043 0.96
PTGS2 0.85 0.001 PTGS2 0.52 0.018
IL6 0.84 0.001 IL6 0.41 0.076
BCL2A1 0.82 0.001 BCL2A1 0.34 0.069
PTX3 0.78 0.001 PTX3 0.13 0.58
ATF3 0.76 0.001 ATF3 0.21 0.26
TNFAIP3 0.75 0.001 TNFAIP3 0.081 0.67
NAB2 0.69 0.001 NAB2 0.23 0.22
TNF 0.54 0.001 TNF 0.25 0.19
CXCL2 0.87 0.001 CXCL2 0.60 0.001
CCL7 0.87 0.001 CCL7 0.66 0.001
STX1A 0.79 0.001 STX1A 0.68 0.001
CCL2 0.74 0.001 CCL2 0.73 0.001
EMP1 0.67 0.001 EMP1 0.57 0.001
CDC42 0.63 0.001 CDC42 0.48 0.008
PTPN7 0.60 0.001 PTPN7 0.66 0.001
MAPK6 0.58 0.001 MAPK6 0.50 0.005
DHRS3 0.58 0.001 DHRS3 0.66 0.001
CD9 0.073 0.70 CD9 0.48 0.008
HSPA1A 0.16 0.41 HSPA1A 0.36 0.005
FABP5 0.27 0.15 FABP5 1
r is Spearman’s correlation coefficient. The PDE4B correlations were
determined in the LADA patients (n  30) because PDE4B upregu-
lation was specific for that group. The FABP5 correlations were
determined in the juvenile-onset type 1 diabetic patients (n  30) for
the same reason (a specific FABP5 upregulation in juvenile-onset
type 1 diabetes). See Fig. 1, the genes in the red box correlate
significantly with PDE4B, and the genes in the blue box correlate
significantly with FABP5.
TABLE 3
The presence of cluster 1 and PDE4B–correlating set and cluster 2 and FABP5–correlating set in the monocytes of different diabetic
groups and control subjects
Definitions
Control
subjects
Juvenile-onset
type 1 diabetes
Adult-onset
type 1 diabetes LADA
Type 2
diabetes
n 94 30 43 30 30
75% of cluster 1 genes positive 10 (9) 10 (3) 28 (12)* 60 (18)† 37 (11)‡
75% of PDE4B correlating set
genes positive 3 (3) 10 (3) 23 (10)† 43 (13)† 17 (5)‡
75% of cluster 2 genes positive 5 (5) 43 (13)‡ 9 (4) 33 (10)‡ 10 (3)
75% of FABP5 correlating set
genes positive 2 (2) 43 (13)‡ 7 (3) 13 (4)* 0
Data are n (%) unless otherwise indicated. For this analysis, 35 extra control subjects were available, so 94 total were studied. Positivity of
the genes is defined as an mRNA expression 1 SD higher than the mean level found in the control subjects. *P  0.05; †P  0.001; ‡P  0.01
vs. control subjects (tested via 	2 tests).
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FIG. 2. Serum levels of PTX3 in cluster 1–positive (n  36) and
–negative subjects (n  73) (patients as well as control subjects). The
definition was as follows: positive, >75% of the cluster 1 genes
positive; negative, <75% of the cluster 1 genes positive. Groups were
compared by ANCOVA analysis with age, sex, and BMI included in the
model. Because normal distribution of PTX3 could not be obtained,
ranks of PTX3 were used in the analysis (28).
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larly. Further investigations are needed to establish con-
sistency and diagnostic and prognostic consequences of
monocyte inflammatory profiles under various storage and
isolation conditions.
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